^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    megestrol

    i
    Other names: BDH 1298
    Company:
    Generic mfg.
    Drug class:
    Progesterone receptor agonist
    6d
    A prospective, randomized, parallel controlled clinical trial of megestrol acetate oral suspension in patients with locally advanced nasopharyngeal carcinoma (ChiCTR2500114759)
    P=N/A, N=68, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New trial
    |
    megestrol • TheraCIM (nimotuzumab)
    6d
    A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients with Cancer Cachexia (ChiCTR2500112934)
    P=N/A, N=495, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New trial
    |
    megestrol
    6d
    To evaluate the efficacy and safety of NEPA combined with Megestrol Acetate versus NEPA combined with Dexamethasone in preventing nausea and vomiting caused by T-Dxd in breast cancer patients (ChiCTR2600116296)
    P4, N=120, Not yet recruiting, Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita
    New P4 trial
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • dexamethasone • megestrol
    6d
    A Multicenter, Randomized, Controlled Phase II Clinical Trial of Nanocrystalline Megestrol Acetate versus Placebo for Anorexia in Patients with Unresectable Hepatocellular Carcinoma Receiving TACE Combined with Targeted and Immunotherapy (ChiCTR2600117241)
    P2, N=88, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New P2 trial
    |
    megestrol
    16d
    Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=68, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P3 trial
    |
    megestrol
    16d
    Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, Northwestern University | Trial primary completion date: Dec 2025 --> Aug 2025
    Trial primary completion date
    |
    megestrol
    23d
    A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P1, N=88, Recruiting, Second Xiangya Hospital of Central South University
    New P1 trial
    |
    megestrol
    28d
    Systematic Exploration of Molecular Mechanisms and Natural Herbal Therapeutic Strategies for Cancer Cachexia. (PubMed, Cancers (Basel))
    The limited efficacy and adverse effects of synthetic agents like megestrol acetate underscore the value of herbal therapies as safer adjunctive strategies...While promising, current evidence remains largely preclinical and mechanistic validation is incomplete. This review consolidates contemporary insights into CC pathogenesis and the bioactivity of herbal interventions, highlighting the need for translational research to bridge preclinical findings with clinical applicability.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IGF1 (Insulin-like growth factor 1) • FBXO32 (F-Box Protein 32)
    |
    megestrol
    1m
    FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov)
    P2/3, N=260, Not yet recruiting, Fudan University
    New P2/3 trial • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    ER positive • MSI-H/dMMR
    |
    Tyvyt (sintilimab) • letrozole • triptorelin • megestrol
    1m
    Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial. (PubMed, Nat Cancer)
    This effect was accompanied by reduced ER genomic binding at canonical binding sites in paired tumor biopsies, indicating reduced ER transcriptional activity. These results support further evaluation of low-dose megestrol, which has two mechanisms for potentially improving breast cancer outcomes in combination with standard antiestrogen therapy: alleviating hot flashes and thereby helping with treatment adherence, as well as a direct antiproliferative effect ( NCT03306472 ).
    P2b data • Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive
    |
    letrozole • megestrol
    2ms
    MATRIX: Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC (clinicaltrials.gov)
    P3, N=60, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    oxaliplatin • megestrol
    2ms
    Treatment of HRD-positive elderly ovarian cancer patient: a case report. (PubMed, Anticancer Drugs)
    Fluzoparib, the domestically developed PARPi in China, has demonstrated significant efficacy in BRCA-mutated ovarian cancer. In the field of supportive care, megestrol acetate (MA) is recommended as the first-line preferred therapeutic agent for cancer-related anorexia by major guidelines, though its role in first-line ovarian cancer therapy remains unexplored, and evidence for its combination with PARPi is lacking...Imaging assessments revealed significant tumor reduction without disease progression or grade ≥3 adverse events observed throughout follow-up. This case highlights the potential of combining PARPi and hormone therapy as a 'chemotherapy-free' precision treatment model for elderly and HRD-positive ovarian cancer patients, offering a promising strategy to balance efficacy and tolerability in a population traditionally underserved by conventional regimens.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    AiRuiYi (fluzoparib) • megestrol